CardiologyOnline.net

Cardiology Xagena

Xagena Mappa
Medical Meeting
XagenaNewsletter
Ematobase.it

Search results for "Sacubitril and Valsartan"

The new drug LCZ696 is a treatment for chronic heart failure. LCZ696 is better than conventional drugs at reducing cardiac death and hospitalization due to heart failure. Now, researchers from Kuma ...


Sacubitril / Valsartan ( Entresto ) has been shown to improve mortality and reduce hospitalizations in patients with heart failure with reduced ejection fraction ( HFrEF ). The effect of combination ...


Elevated serum uric acid concentration ( SUA ) has been associated with an increased risk of cardiovascular disease, but this may be due to unmeasured confounders. Researchers have examined the as ...


Data from the TRANSITION study presented at the European Society of Cardiology ( ESC ) Congress in Munich ( Germany ) has shown that Entresto ( Sacubitril / Valsartan ) can be initiated early and safe ...


Because neprilysin is involved in the degradation of amyloid-beta, there is concern that the angiotensin-neprilysin inhibitor Sacubitril - Valsartan ( Entresto ) could increase the risk for dementia. ...


Inhibition of neprilysin, an enzyme degrading natriuretic and other vasoactive peptides, is beneficial in heart failure with reduced ejection fraction ( HFrEF ), as shown in PARADIGM-HF which compared ...